Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Carlini, P.
Right arrow Articles by Cognetti, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carlini, P.
Right arrow Articles by Cognetti, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:1539-1543, 2001
© 2001 European Society for Medical Oncology

research-article

Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): Is a clinical benefit still achievable?

P. Carlini1,, A. Frassoldati2, S. De Marco1, A. Casali1, E. M. Ruggeri1, M. Nardi1, P. Papaldo1, A. Fabi1, F. Paoloni1 and F. Cognetti1

1Department of Medical Oncology, Regina Elena National Cancer Institute Rome
2Division of Medical Oncology. University of Modena Italy

P Carlini, MD, Division of Medical Oncology A Regina Elena National Cancer Institute Via Elio Chianesi, 53 00144 Rome, Italy E-mail pcarlini{at}iol.it

Background There are few clinical data on the sequential use of aromatase inhibitors (Al) This paper focuses on the relevance of clinical benefit CB (CR + PR + SD ≥6 months) in postmenopausal metastatic breast cancer (MBC) patients treated with the steroidal aromatase inhibitor (SAI) formestane (FOR), who had already received non-steroidal aromatase inhibitor (nSAI) letrozole (LTZ) or anastrozole (ANZ)

Patients and methods Twenty postmenopausal women with MBC were analysed in this retrospective two-centre study with the sequence nSAI-FOR When receiving ANZ, 1 of 11 achieved a complete response and 9 of 11 a stable disease ≥ 6 months, and receiving LTZ 1 of 9 achieved a partial response and 4 of 9 a stable disease ≥6 months The analysis of the entire population treated with FOR showed an overall CB of 55% (11 of 20) with a median duration of 15 months and median time to progression (TTP) of 6 months

Conclusions Formestane 250 mg once bi-weekly seems to be an attractive alternative third-line hormonal therapy for the treatment of patients with MBC, previously treated with nSAI

anastrozole, aromatase inhibitors, breast cancer, advanced/metastatic, formestane, hormone therapy, letrozole


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
W. R. Miller, J. Bartlett, A. M. H. Brodie, R. W. Brueggemeier, E. di Salle, P. E. Lonning, A. Llombart, N. Maass, T. Maudelonde, H. Sasano, et al.
Aromatase Inhibitors: Are There Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do They Matter?
Oncologist, August 1, 2008; 13(8): 829 - 837.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
R. Ponzone, P. Mininanni, E. Cassina, F. Pastorino, and P. Sismondi
Aromatase inhibitors for breast cancer: different structures, same effects?
Endocr. Relat. Cancer, March 1, 2008; 15(1): 27 - 36.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Colozza, E. de Azambuja, N. Personeni, F. Lebrun, M. J. Piccart, and F. Cardoso
Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer
Oncologist, March 1, 2007; 12(3): 253 - 270.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
I. E. Smith and M. Dowsett
Aromatase Inhibitors in Breast Cancer
N. Engl. J. Med., June 12, 2003; 348(24): 2431 - 2442.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.